Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5316387 | 0.80 | GRIN2D (0.31) | KIF11 | |
| SCHEMBL6165008 | 0.76 | TAAR1 (0.38) | — | |
| SCHEMBL8371918 | 0.76 | KIF11 (0.44) | KIF11DNMT1 | |
| SCHEMBL8371919 | 0.76 | KIF11 (0.44) | KIF11DNMT1 | |
| SCHEMBL9409970 | 0.74 | KIF11 (0.47) | KIF11DNMT1 | |
| SCHEMBL9409962 | 0.74 | KIF11 (0.47) | KIF11DNMT1 | |
| SCHEMBL7846363 | 0.74 | KIF11 (0.31) | KIF11 | |
| SCHEMBL12944846 | 0.67 | KIF11 (0.56) | KIF11DNMT1 | |
| SCHEMBL5020894 | 0.67 | KIF11 (0.44) | KIF11DNMT1 | |
| SCHEMBL9926339 | 0.67 | KIF11 (0.44) | KIF11DNMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1087981-B1 | PRENYL TRANSFERASE INHIBITORS | SOD CONSEILS RECH APPLIC (FR) | 2006-04-12 | — | — | EP | disclosed |
| US-6313109-B2 | ANTIPROLIFERATIVE AGENTS; TREATING TUMORS, RESTENOSIS | SOCIETE DE CONSEILS DE RECHERCHES D'APPLICATIONS SCIENTIFIQUES, SAS (FR) | 2001-11-06 | — | — | US | disclosed |
| EP-1094810-A1 | USE OF PRENYLTRANSFERASE INHIBITORS FOR PREPARING A MEDICINE FOR TREATING PATHOLOGIES RESULTING FROM HETEROTRIMERIC G PROTEIN MEMBRANE FIXATION | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2001-05-02 | — | — | EP | disclosed |
| US-20010000344-A1 | Prenyl transferase inhibitors | BIOMEASURE INCORPORATED | 2001-04-19 | — | — | US | disclosed |
| US-6180619-B1 | TREATING TUMORS OR RESTENOSIS | BIOMEASURE, INCORPORATED | 2001-01-30 | — | — | US | disclosed |
| WO-2000002558-A1 | USE OF PRENYLTRANSFERASE INHIBITORS FOR PREPARING A MEDICINE FOR TREATING PATHOLOGIES RESULTING FROM HETEROTRIMERIC G PROTEIN MEMBRANE FIXATION | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2000-01-20 | — | — | WO | disclosed |
| EP-0836383-A1 | COMBINATIONS OF INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | Merck & Co., Inc. (US) | 1998-04-22 | — | — | EP | disclosed |
| US-5736539-A | ANITCARCINOGENIC AGENTS | MERCK & CO., INC. (US) | 1998-04-07 | — | — | US | disclosed |
| WO-1997001275-A1 | COMBINATIONS OF INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1997-01-16 | — | — | WO | disclosed |
| EP-0703905-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO. INC. (US) | 1996-04-03 | — | — | EP | disclosed |
| WO-1995000497-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1995-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010000344-A1 | Prenyl transferase inhibitors | FNTA, FNTB, RCE1 | KIF11 4045/4885DNMT1 3415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.